Phase 3 head-to-head ENDEAVOR study demonstrates superiority of Kyprolis® (carfilzomib) over Velcade® (bortezomib) in patients with relapsed multiple myeloma
2 March 2015 | By Amgen
Study met primary endpoint of progression-free survival patients receiving Kyprolis lived twice as long without disease progression...